Version history

{
  "session_id": "sess_SDA-2026-04-04-SDA-2026-04-04-gap-debate-20260403-222618-c698b06a_20260412-174727",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Assessment: Metabolic Biomarkers for Therapeutic Response vs. Disease Progression in Neurodegeneration Trials\n\n---\n\n## Executive Summary\n\nThe Theorist's framework is mechanistically sophisticated but carries the translational risk endemic to metabolic biomarker proposals: the inference from molecular mechanism to clinical biomarker validity requires a chain of assumptions that often breaks under real-world trial conditions. I will identify where this framework can be grounded and where it requires recalibration relative to the Alzheimer's clinical development landscape.\n\n---\n\n## 1. Hypotheses with Highest Translational Potential\n\n### Hypothesis A: Neurofilament Light Chain (NfL) as Metabolic-Injury Interface\n\nDespite not appearing in the Theorist's proposals, **NfL is the existing metabolic/injury biomarker most suited to distinguishing therapeutic response from disease progression** in current Alzheimer's trials. It is a structural protein released with neuroaxonal injury whose blood and CSF concentrations reflect the net state of neurodegeneration. In the context of metabolic dysfunction, NfL represents the *downstream integration point",
  "tokens_used": "293"
}